November 11, 2020 08:00 AM EST

Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors

Nicole DeFeudis

Editor

A year after Cirius Therapeutics’ lead NASH drug flopped in a large Phase IIb trial, the biotech’s chief business and financial officer Brian Farmer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors

Nicole DeFeudis

Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Corrected: Trump's broad tariffs could mark a 'double whammy' for pharma after FDA cuts

Day after mass FDA firings, new commissioner addresses remaining staff, focusing on 'MAHA' vision

FDA cuts stir buyer’s remorse for some biopharma leaders, once excited by Trump

Q&A: John Crowley warns biotech is 'dangerously close' to breaking, as tariff threat, markets batter industry

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Small biotech Inipharm lands $35M to take new NASH ap­proach, di­verg­ing from RNAi com­peti­tors

Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors